Purpose of Review Pitt-Hopkins syndrome (PTHS) is a rare neurodevelopmental disorder that results from mutations of the clinically pleiotropic transcription factor 4 (TCF4) gene. Mutations in the genomic locus of TCF4 on chromosome 18 have been linked to multiple disorders including 18q syndrome, schizophrenia, Fuch's corneal dystrophy, and sclerosing cholangitis. For PTHS, TCF4 mutation or deletion leads to the production of a dominant negative TCF4 protein and/or haploinsufficiency that result in abnormal brain development. The biology of TCF4 has been studied for several years in regard to its role in immune cell differentiation, although its role in neurodevelopment and the mechanisms resulting in the severe symptoms of PTHS are not well studied. Recent Findings Here, we summarize the current understanding of PTHS and recent findings that have begun to describe the biological implications of TCF4 deficiency during brain development and into adulthood. In particular, we focus on recent work that has looked at the role of TCF4 biology within the context of PTHS and highlight the potential for identification of therapeutic targets for PTHS. Summary PTHS research continues to uncover mutations in TCF4 that underlie the genetic cause of this rare disease, and emerging evidence for molecular mechanisms that TCF4 regulates in brain development and neuronal function is contributing to a more complete picture of how pathology arises from this genetic basis, with important implications for the potential of future clinical care.
Introduction
The rare developmental disorder, Pitt-Hopkins Syndrome (PTHS), arises from haploinsufficiency of TCF4 (ITF2, SEF2, E2-2) as a result of autosomal dominant mutations at this gene locus on chromosome 18 [1-3, 4•, 5] . Unfortunately in addition to having multiple names in the literature, TCF4 (GeneID:6925, OMIM:602272) shares its acronym with T cell factor 4 that is an alternate name for transcription factor 7-like 2 (TCF7L2), a protein implicated in type-2 diabetes through its role in the Wnt signaling pathway and whose gene is located on chromosome 10 (10q25.3) [6] . This confusion has been thoughtfully addressed in many PTHS manuscripts and reviews, but should continue to be a point to recognize for clarity [7, 8] .
Since the first description of Pitt-Hopkins syndrome as a condition of severe intellectual disability (ID) manifesting with breathing abnormalities and characteristic facial features [9] , proposals have been suggested to standardize a set of clinical phenotypes of the condition in order to efficiently diagnose and identify patients with this rare disorder [5, 10] .
Cognition and behavioral phenotypes of PTHS patients has
This article is part of the Topical Collection on Neurogenetics and Psychiatric Genetics been reported and found to strongly correlate to behavior criteria for autism spectrum disorders (ASD), including severe impairments in communication and language, difficulties in social engagement, fascinations with specific objects, and stereotypical repetitive motor behaviors [11] . Many patient studies confirm reports that PTHS children have happy dispositions [10, 11] , though this characteristic is not completely universal to all patient cohorts [12] . This discrepancy may be explained by additional observations that happy dispositions are also described as contentment, thus not directly a result of social or environmental interactions and strengthening the argument that PTHS behavioral deficits fall into the spectrum of ASD behavioral and social deficits [11] .
Due to phenotypes of PTHS, such as epilepsy, gastrointestinal complications, distinct facial characteristics, severe intellectual disability (ID), and language deficits that highly overlap with similar encephalopathies and autism spectrum disorders (ASD), there is an immediate need for patients and families to more readily achieve a differential diagnosis rather than cycle through clinical testing for other more common conditions, thus delaying important and accurate answers [10] . Patients are commonly only referred for possible PTHS screening after other tests find that they do not carry a MECP2 mutation of Rett syndrome, a UBE3A mutation of Angelman syndrome, or a ZFHX1B mutation of Mowat-Wilson syndrome [5, 10, 12] . A complication for early diagnosis of PTHS is that normal growth parameters are often observed at birth, however, recent studies have suggested that stereotypical facial gestalt and signs of delayed mental development can allow for PTHS diagnosis within the first year of life [5, 12] . For instance, hypotonia which is a commonly identified trait among PTHS patients was noted to be observed in many of the patients during the neonatal period in one set of case reports [5] . The emerging description of a specific set of phenotypic traits associated with PTHS provides an opportunity to uncover the direct genetic and molecular mechanisms that drive these particular traits, hopefully illuminating potential early-intervention therapies for PTHS and related disorders.
The diagnosis of PTHS is currently based upon severe ID and behavioral and cognitive developmental delay accompanied by a typical facial gestalt that includes a large mouth with a tented upper lip, a broad and/or beaked nasal bridge, short philtrum, prominent Cupid's bow, deep-set eyes, squared forehead, and overfolded ear helix [3, 5, 13] . Breathing abnormalities and seizures have also been associated with individuals identified with a chromosome 18 deletion (18q-) that encompasses TCF4 [14] .
Identifying the resulting haploinsufficiency of TCF4 due to heterozygous mutations in the gene has precipitated the growing literature identifying new patients and novel PTHS-linked mutations [1, 3] . Mutations have typically been reported in the basic helix-loop-helix (bHLH) domain where the possibility for disruption of normal E-protein binding function is high [1, 4•, 12, 15-17] . Not all mutations result in complete loss of TCF4 protein function, and evidence for dominant-negative effects of mutant protein has been observed [4•, 18] . Reported PTHS-linked mutations that are located outside of this bHLH region have not been shown to lead to functional deficiencies in TCF4 protein, and how they result in disease remains an open question [4•] .
Genotype-phenotype analysis is leading to other novel findings that may play a role in understanding the biological functions of TCF4. Missense mutations were identified as increasing the probability that an individual would develop seizures in one study that confirmed TCF4 deletion in several patients that did not present with seizures [19] . This finding of a clear genotype-phenotype correlation has not been found in other patient populations with truncating mutations, deletions, or missense mutations [5] . The absence of a clear correlation suggests that a general TCF4 haploinsufficiency is the broad basis to the central phenotypic traits of PTHS. However, variability in phenotype and symptom severity across patients seems to be a characteristic of PTHS, and as new patients are described along with their genetic mutation, linking the specifics of TCF4 biology to pathophysiology will help address the lack of current therapeutic strategies.
Treatments in PTHS
Current clinical care for PTHS patients mainly comprises treatment aimed at alleviating severe symptoms that are understood and commonly treated outside of the context of this rare disorder. Improving GI dysfunction, treating seizures, and applying ASD therapies to support social and cognitive development are some of the current means for improving the quality of life for PTHS patients. A consensus for care and proven evidence-based interventions are still lacking though, and the limited amount of therapeutic options has been noted in previous PTHS reviews [8] . The small overall patient population inhibits an ability to draw firm conclusions from various case reports, especially with the biological mechanisms of the underlying disorder far from defined.
In the course of addressing epileptic seizures in a PTHS patient, it was observed that administration of valproate also improved the clinical presentations of breathing abnormalities [20] . The correction of breathing abnormalities is also an outcome of one of the other few reports of PTHS treatments [21] . Bouts of hyperventilation resulting in severe apnea were treated in two patients using acetazolemide to create a global tissue metabolic acidosis that would stimulate breathing through the central chemoreceptor response [21] . The mechanism for this effect is still unclear; the rationale for treatment relies mostly on the previously successful use of acetazolemide to counteract sleep apneas and hyperventilation symptoms seen at altitude [22, 23] . However, novel treatments for the constellation of PTHS deficits and symptoms have been mostly elusive for patients of this rare disorder. In particular, therapies to address the cognitive deficits in this developmental disorder have seemed out of reach due to a lacking description of TCF4 regulation in brain development and function. We will describe recent work that addresses this gap in knowledge with the aim of contributing to a starting point for the conversation about targeted, biology-based therapeutics.
Understanding TCF4 Biology
TCF4 is a bHLH protein further characterized as an E-protein due to its binding of Ephrussi box (E-box) DNA motif (CANNTG) when homodimerized with itself or heterodimerized with other bHLH transcription factors (TF) [24] . There have been at least 18 reported splice variants of TCF4, differentiated by N-terminus variations that result from the alternative splicing of 5′ exons [25] . The highly conserved bHLH domain motif allows for recognition of a variety of dimerization partners to create E-box binding [26, 27] . Alternative splicing that can alter the affinity for particular dimerization partners leads to diverse opportunities for transcriptional regulation under various physiological contexts [28, 29] . This context dependence has recently become relevant to understanding PTHS biology. The full-length human isoform, TCF4-B, has been described through in vitro investigations to activate transcription [12, 15] . However, this variant has also been reported to be a repressor of transcription in various studies [30] [31] [32] , and knockdown of TCF4 was found to relieve repression of ion channel expression and thus regulate neuronal excitability [33•] .
The regulation of neuronal excitability by TCF4 has intriguing consequences when considered in the context of previously reported Ca 2+ -dependence of E-protein mediated transcription [34] [35] [36] [37] . Ca 2+ and Ca 2+ -binding proteins have been shown to influence dimer binding at the bHLH transcription factor domain [38] [39] [40] [41] . Evidence that homodimerization binding rates are more sensitive to the inhibitory regulation of these Ca 2+ -mediated mechanisms suggests that differential control of transcriptional targets occurs with activity depending on the E-protein binding partners involved [38] . Activity is a well-known regulator of neuronal development mediating aspects of cell migration and morphology [42] [43] [44] [45] . The finely tuned process of neuronal development unfolds against a fluctuating background of Ca 2+ signaling from multiple sources including voltage-gated Ca 2+ -channels and NMDA receptors [46] . Activity-dependent developmental processes reflected in the functional morphology of the brain have been known since the description of ocular dominance column formation [47] , and the interaction between Ca 2+ -mediated mechanisms and activity is well-known to influence developmental plasticity in the visual cortex [48] . Many mechanisms of cortical development have been well reviewed including the role of activity [49, 50] , the regulation of calcium-dependent processes [51] [52] [53] , and the role of bHLH transcription factors in corticogenesis [54] . Integrating new findings on TCF4 biology into these broader contexts will be essential to the understanding of the severe neurological deficits in PTHS. If the feedback from Ca 2+ -mediated mechanisms during nascent activity in the developing brain plays an important role in shaping TCF4 expression and activity, there may be important implications for circuit formation and its dysregulation under pathophysiological conditions.
Severe developmental outcomes resulting from insufficient TCF4 were evident in animal models with the first reported descriptions of the Tcf4 homozygous knockout mice that fail to survive through the first postnatal day [55] . Further studies have shown specific developmental deficits in the pontine nucleus within the hindbrain despite a lack of other gross developmental deficits in these Tcf4 knockout mice [56] . It has been noted that this hindbrain developmental deficit may be particularly relevant to PTHS biology, as the pontine nucleus plays a role in the hindbrain control of breathing [56, 57] . Confirmation of a corresponding developmental insult in the PTHS patients has yet to be reported, so it remains unclear if patient breathing abnormalities arise from the central pattern generators involved in breathing control in the hindbrain. However, in addition to describing the developmental phenotype of the pontine nucleus, Flora et al. further determined that normal development of this brain region was dependent on specific heterodimerization of Tcf4 with another bHLH transcription factor, Atoh1 (Math1). The regulation of development for these Atoh-dependent regions has been shown to be critical for respiratory rhythmogenesis and oscillatory coordination of the control of breathing [58, 59] . This conclusion, that particular Tcf4 heterodimers fill a distinct role in the tight control of genetic programs during the development of highly specific brain regions, highlights both a great success of understanding TCF4 biology and the great challenge of complexity when it comes to determining realistic therapeutic strategies for PTHS patients.
A mouse model for Tcf4 haploinsufficiency has provided insight into the molecular mechanisms that result as a consequence of TCF4 deficiency during development [55] . Originally generated as a model of constitutive germline deletion of one Tcf4 allele, our recent work has shown that a truncated TCF4 protein is in fact expressed in these mice [18] . Furthermore, we have shown this truncated protein is capable of binding to full length TCF4, confirming other previous reports that this transgenic PTHS mouse model may produce TCF4 haploinsufficiency through a dominantnegative binding mechanism [4•, 18] . Although this model does not produce a complete allelic germline deletion, it still represents a powerful model for understanding PTHS biology, as the disruption of normal protein dimerization and DNA binding is a key element of the point mutations or other TCF4 gene disruptions that result in PTHS [4] . A description of behavioral phenotypes in the PTHS mouse was recently reported [60•] and was shown to exhibit deficits in line with previously reported mouse models of autism including motor coordination deficits, repetitive behaviors and grooming, preference for isolation over social interaction, reduced vocalizations, and hyperactivity [61] [62] [63] . Additionally, the PTHS mouse displays gastrointestinal (GI) deficiencies in the upper GI and distal colon, providing further connection to common human PTHS patient phenotypes including GI disturbances like constipation [64] .
We have recently reported on the role of TCF4 to regulate neuronal excitability in the medial prefrontal cortex of both the PTHS mouse and another in vivo model of PTHS that replicates TCF4 haploinsufficiency prior to neurogenesis [33•] . Abnormal neuronal function in these rodent models may correspond to a possible mechanism of the cognitive deficits associated with the corresponding prefrontal association cortex in humans with psychiatric disorders [65] . Our study identified multiple ion channels that are capable of being regulated by TCF4 and alter neuronal spiking under conditions of TCF4 dysfunction. One channel gene in particular, Scn10a, is interestingly ectopically overexpressed due to TCF4 haploinsufficiency [33•] . Indeed, neuronal firing was normalized through both pharmacological and genetic rescue experiments aimed at blocking the function and expression of SCN10a. This peripherally expressed ion channel has not previously been reported to play a role in neuronal function within the CNS [66, 67] , and thus presents a possible novel target for therapeutics aimed at correcting circuit function and cognitive deficits in PTHS.
The pattern of TCF4 expression through the life span that is conserved across species, peaking prior during late prenatal life, is clearly suggestive of an important role in development [33•] . Although it declines from its developmental peak, TCF4 expression is maintained throughout life [33•] . Recent experiments have shown that this expression past development has functional consequences for the establishment of synaptic connections in the drosophila neuromuscular junction [68•] . In this preparation, TCF4 was shown to restrict neurite branching and synapse number [68•] . Interestingly, TCF4 was found to repress neurexin expression in these postmitotic neurons [68•] , establishing a link to the synaptically associated gene that is linked to multiple psychiatric disorders and specific cases of a PTHS-like disorder in patients that do not appear to have a TCF4 mutation [69] . This work highlights the developing description of ASD-linked genes across multiple independently identified disorders. It also points to a challenge of developing strategies to treat PTHS symptoms, namely, that TCF4 may play an important function not only in neurodevelopment, but also in the maintenance of neuronal mechanisms that might contribute to cognitive deficits.
Recent work has also identified the dysregulation of transcription and DNA methylation in genes important to learning and memory in the PTHS mouse [60•] . Both a non-specific HDAC inhibitor, the small molecule suberoylanilide hydroxamic acid (SAHA), and a subtype specific Hdac2 knockdown by antisense oligonucleotides (ASOs) were able to normalize the expression of some learning and memory related genes that are dysregulated in this PTHS model [60•] . Both HDAC inhibition treatments were also shown to improve deficiencies exhibited by the PTHS mice in certain learning and memory tasks [60•] . This is a promising avenue for potentially reversing cognitive deficits in PTHS during a postdevelopment therapeutic window.
TCF4 Biology in Other Psychiatric Disorders
TCF4 is a clinically pleiotropic gene and its role in the pathology of other psychiatric disorders may be very relevant to understanding the biological implications of haploinsufficiency in PTHS. Genome wide association studies have identified common single nucleotide polymorphisms within TCF4 introns that are associated with a diagnosis of schizophrenia [70] [71] [72] . Furthermore, some common variants are associated with schizophrenia-linked cognitive endophenotypes in both patients and control carriers [73] [74] [75] . However, the mechanisms for these associations are not known. The risk for psychiatric disease and dysregulated cortical development seems to be a shared outcome whether TCF4 expression is disrupted, as in PTHS, or overexpressed. Duplication of TCF4 is known to result in developmental delays across neurodevelopmental diagnoses [76] . A partial duplication of TCF4 was found through analysis of copy number variations in DNA from the brain of major depressive disorder patients [77] . Possibly suggestive of common mechanisms of ASD pathophysiology, the upregulation of TCF4 expression has been shown in another disorder on the autism spectrum, 2q23.1 deletion syndrome [78] . Indeed, the complexity of phenotype outcome due to variable expression of TCF4 isoforms is emerging from reports describing a range of cases of TCF4-linked ID. An inherited familial translocation that results in both disrupted and overexpressed transcripts depending on the specific TCF4 isoform has been associated with mild ID [79] . Forms of developmental delays with ID that do not exhibit other characteristics of PTHS have been found to result when TCF4 mutations lead to reduced expression of particular isoforms [80, 81] . Exome sequencing has also identified de novo TCF4 mutations in children with severe nonsyndromic forms of sporadic ID [82, 83] . The range of TCF4-associated disorders is representative of the myriad of potential interactions the protein encounters during regulation of expression at multiple target genes. While the range of described cellular and molecular phenotypes is diverse and growing for psychiatric disorders and ASD in particular, these insights are contributing hope that there are underlying pathways and common systems to be uncovered [84, 85] .
Conclusion
The severe and systemic developmental phenotypes of PTHS present a formidable challenge to researchers and clinicians interested in developing effective therapeutics to enhance the quality of life for these patients. Evidence that the expression of TCF4 is maintained in the brain past an early peak of expression during development [33•] suggests that treatment of PTHS cognitive deficits may be possible if TCF4 plays a significant role in the maintenance of neuronal function through adulthood. This is especially important for a rare disease like PTHS that is most commonly acquired through random spontaneous mutation, where identification of the genetic abnormality and developmental deficits occur well past birth.
Multiple recent studies have begun to highlight potential therapeutic routes that may provide hope for PTHS patients and their families. Regulators of neuronal excitability have been shown to play a direct role in neuronal dysfunction related to TCF4 haploinsufficiency, specifically an ectopically expressed ion channel SCN10a may be a promising target for normalizing neuronal function in PTHS [33•] . Evidence that TCF4 functions postnatally in postmitotic neurons to regulate synapse formation [68•] , and results that HDAC inhibition can improve cognitive behaviors of a PTHS mouse model [60• ] both also present an emerging picture that amelioration of the widespread developmental phenotypes of PTHS may be a future possibility.
